Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors

PURPOSE: To conduct a phase I study determining the safety, pharmacokinetics and preliminary efficacy of EP-100, a novel anticancer drug consisting of natural luteinizing-hormone-releasing hormone (LHRH) ligand linked to a cationic membrane-disrupting peptide. METHODS: Patients with advanced, solid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Curtis, Kelly K., Sarantopoulos, John, Northfelt, Donald W., Weiss, Glen J., Barnhart, Kerry M., Whisnant, John K., Leuschner, Carola, Alila, Hector, Borad, Mitesh J., Ramanathan, Ramesh K.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4000412/
https://ncbi.nlm.nih.gov/pubmed/24610297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2424-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados